Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VINCENT: Venetoclax + azacitidine vs intensive chemotherapy in NPM1-mutated AML
2021-003248-26Phase 2Active
- Sponsor
- Technische Universität Dresden
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of venetoclax in acute myeloid leukemia (AML) (2 arms), sponsored by Technische Universität Dresden. Primary endpoint: Modified event-free survival. Started Jan 2023; status: active.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2021-003248-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003248-26.